A detailed history of Snyder Capital Management L P transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Snyder Capital Management L P holds 4,063,367 shares of HALO stock, worth $185 Million. This represents 5.07% of its overall portfolio holdings.

Number of Shares
4,063,367
Previous 4,039,912 0.58%
Holding current value
$185 Million
Previous $212 Million 9.9%
% of portfolio
5.07%
Previous 4.92%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.3 - $64.42 $1.2 Million - $1.51 Million
23,455 Added 0.58%
4,063,367 $232 Million
Q2 2024

Aug 14, 2024

SELL
$37.81 - $52.4 $2.92 Million - $4.05 Million
-77,315 Reduced 1.88%
4,039,912 $212 Million
Q1 2024

May 15, 2024

BUY
$33.68 - $41.95 $13.7 Million - $17.1 Million
407,628 Added 10.99%
4,117,227 $167 Million
Q4 2023

Feb 14, 2024

SELL
$33.32 - $42.1 $20.5 Million - $25.9 Million
-614,633 Reduced 14.21%
3,709,599 $137 Million
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $26,251 - $31,701
720 Added 0.02%
4,324,232 $165 Million
Q2 2023

Aug 14, 2023

BUY
$30.28 - $38.74 $857,771 - $1.1 Million
28,328 Added 0.66%
4,323,512 $156 Million
Q1 2023

May 15, 2023

BUY
$32.86 - $55.7 $10.2 Million - $17.3 Million
311,370 Added 7.82%
4,295,184 $164 Million
Q4 2022

Feb 14, 2023

SELL
$40.06 - $59.44 $17.4 Million - $25.9 Million
-435,114 Reduced 9.85%
3,983,814 $227 Million
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $11.9 Million - $16 Million
308,754 Added 7.51%
4,418,928 $175 Million
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $2.51 Million - $3.25 Million
67,268 Added 1.66%
4,110,174 $181 Million
Q1 2022

May 16, 2022

SELL
$31.97 - $41.06 $699,279 - $898,105
-21,873 Reduced 0.54%
4,042,906 $161 Million
Q4 2021

Feb 14, 2022

BUY
$31.82 - $40.75 $20.3 Million - $26 Million
637,303 Added 18.59%
4,064,779 $163 Million
Q3 2021

Nov 15, 2021

BUY
$38.47 - $46.42 $9.66 Million - $11.7 Million
251,072 Added 7.9%
3,427,476 $139 Million
Q2 2021

Aug 16, 2021

BUY
$38.84 - $51.31 $9.93 Million - $13.1 Million
255,544 Added 8.75%
3,176,404 $144 Million
Q1 2021

May 17, 2021

SELL
$39.51 - $51.45 $15 Million - $19.5 Million
-379,141 Reduced 11.49%
2,920,860 $122 Million
Q4 2020

Feb 16, 2021

SELL
$25.81 - $43.62 $2.06 Million - $3.49 Million
-79,926 Reduced 2.36%
3,300,001 $141 Million
Q3 2020

Nov 13, 2020

SELL
$25.74 - $29.63 $554,516 - $638,319
-21,543 Reduced 0.63%
3,379,927 $88.8 Million
Q2 2020

Aug 14, 2020

BUY
$16.25 - $26.81 $136,711 - $225,552
8,413 Added 0.25%
3,401,470 $91.2 Million
Q1 2020

May 15, 2020

SELL
$13.9 - $21.83 $1.43 Million - $2.24 Million
-102,835 Reduced 2.94%
3,393,057 $61 Million
Q4 2019

Feb 14, 2020

BUY
$14.93 - $19.53 $11.6 Million - $15.1 Million
774,034 Added 28.44%
3,495,892 $62 Million
Q3 2019

Nov 14, 2019

SELL
$15.2 - $17.69 $108,634 - $126,430
-7,147 Reduced 0.26%
2,721,858 $42.2 Million
Q2 2019

Aug 14, 2019

SELL
$14.75 - $17.26 $1.44 Million - $1.68 Million
-97,596 Reduced 3.45%
2,729,005 $46.9 Million
Q1 2019

May 15, 2019

SELL
$13.94 - $17.58 $99,782 - $125,837
-7,158 Reduced 0.25%
2,826,601 $45.5 Million
Q4 2018

Feb 14, 2019

BUY
$13.33 - $18.66 $5.95 Million - $8.33 Million
446,409 Added 18.7%
2,833,759 $41.5 Million
Q3 2018

Nov 14, 2018

BUY
$16.68 - $18.41 $191,386 - $211,236
11,474 Added 0.48%
2,387,350 $43.4 Million
Q2 2018

Aug 14, 2018

BUY
$16.87 - $20.3 $393,931 - $474,025
23,351 Added 0.99%
2,375,876 $40.1 Million
Q1 2018

May 14, 2018

SELL
$17.06 - $21.2 $238,072 - $295,846
-13,955 Reduced 0.59%
2,352,525 $46.1 Million
Q4 2017

Feb 13, 2018

SELL
$16.75 - $20.8 $1.68 Million - $2.08 Million
-100,204 Reduced 4.06%
2,366,480 $47.9 Million
Q3 2017

Nov 14, 2017

BUY
$11.76 - $17.4 $29 Million - $42.9 Million
2,466,684
2,466,684 $42.8 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.36B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Snyder Capital Management L P Portfolio

Follow Snyder Capital Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Snyder Capital Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Snyder Capital Management L P with notifications on news.